Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase NA 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Melanoma 12Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 11Colorectal Neoplasms 9Triple Negative Breast Neoplasms 8Neoplasms 6Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Renal Cell 5Stomach Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 4Glioblastoma 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lung Neoplasms 2Liver Neoplasms 2Hematologic Diseases 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Advanced Solid Tumors 2Advanced Solid Tumor 2Adenocarcinoma 2von Hippel-Lindau Disease 1

Interventions

Gemcitabine 6pembrolizumab 5toripalimab 2fludarabine 2Valproic Acid 2Valganciclovir 2Injections 2Cyclophosphamide 2Cisplatin 2130-nm albumin-bound paclitaxel 2tislelizumab 1spartalizumab 1sapropterin 1fosaprepitant 1fludarabine phosphate 1camrelizumab 1Surgical Procedures, Operative 1Specimen Handling 1SHR-1701 1Protons 1Proton Therapy 1Panobinostat 1Medicare Part B 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Floxuridine 1Everolimus 1Dexamethasone 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Nasopharyngeal Carcinoma × spartalizumab × Clear all
NCT03891953 2026-01-21

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Novartis

Phase 1 Active not recruiting
98 enrolled
BreastDermatologicHead & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡